company background image
APTX logo

Aptinyx OTCPK:APTX Stock Report

Last Price

US$0.096

Market Cap

US$6.5m

7D

10.9%

1Y

-73.4%

Updated

03 Jan, 2024

Data

Company Financials

APTX Stock Overview

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders.

APTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Aptinyx Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aptinyx
Historical stock prices
Current Share PriceUS$0.096
52 Week HighUS$0.72
52 Week LowUS$0.009
Beta1.22
1 Month Change46.12%
3 Month Change43.07%
1 Year Change-73.43%
3 Year Change-97.32%
5 Year Change-99.48%
Change since IPO-99.52%

Recent News & Updates

Recent updates

Aptinyx musculoskeletal pain drug NYX-2925 fails mid-stage study

Aug 12

We're Keeping An Eye On Aptinyx's (NASDAQ:APTX) Cash Burn Rate

Aug 18
We're Keeping An Eye On Aptinyx's (NASDAQ:APTX) Cash Burn Rate

Aptinyx: CNS Drug Discoverer With Depressed Price

Jul 21

Aptinyx updates on mid-stage clinical program for PTSD therapy

Jun 15

Aptinyx (NASDAQ:APTX) Is In A Good Position To Deliver On Growth Plans

Apr 13
Aptinyx (NASDAQ:APTX) Is In A Good Position To Deliver On Growth Plans

Did You Miss Aptinyx's (NASDAQ:APTX) 15% Share Price Gain?

Mar 09
Did You Miss Aptinyx's (NASDAQ:APTX) 15% Share Price Gain?

What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?

Jan 30
What Kind Of Shareholders Hold The Majority In Aptinyx Inc.'s (NASDAQ:APTX) Shares?

Aptinyx recommences Phase 2 study of NYX-2925

Jan 04

Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?

Dec 26
Have Insiders Been Buying Aptinyx Inc. (NASDAQ:APTX) Shares This Year?

What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 27
What Type Of Returns Would Aptinyx's(NASDAQ:APTX) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Shareholder Returns

APTXUS BiotechsUS Market
7D10.9%-2.1%-0.1%
1Y-73.4%10.4%28.4%

Return vs Industry: APTX underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: APTX underperformed the US Market which returned 22.4% over the past year.

Price Volatility

Is APTX's price volatile compared to industry and market?
APTX volatility
APTX Average Weekly Movement19.1%
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: APTX's share price has been volatile over the past 3 months.

Volatility Over Time: APTX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201512Craig Jalberthttps://www.aptinyx.com

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc.

Aptinyx Inc. Fundamentals Summary

How do Aptinyx's earnings and revenue compare to its market cap?
APTX fundamental statistics
Market capUS$6.50m
Earnings (TTM)-US$66.09m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$35.74m
Gross Profit-US$35.74m
Other ExpensesUS$30.35m
Earnings-US$66.09m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.98
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio137.5%

How did APTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.